Meeting Coverage:

American Academy of Ophthalmology

AAO: 2019

Gene Therapy for Wet AMD

Show Description +

Szilárd Kiss, MD, explains the structure and 6-month results of the OPTIC trial, a phase 1 study that evaluated ADVM-022 (Adverum Biotechnologies), a novel intravitreal gene therapy for the treatment of wet age-related macular degeneration.

Posted: 10/21/2019

Up Next


ABC to Block VEGF-A Isoforms

Charles C. Wykoff, MD, PhD

Surgery for Viral Retinitis

J. Fernando Arevalo, MD, PhD, FACS

Iridocorneal Endothelial Syndrome

Lauren S. Blieden, MD

Advanced Diagnostics in Refractive Surgery: Epithelial Mapping and Phakic IOL Sizing

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Efficacy of Presbyond for the Correction of Presbyopia

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Autonomous AI in Ophthalmology

Michael D. Abramoff, MD, PhD

CXL for Infectious Keratitis

Farhad Hafezi, MD, PhD, FARVO

MIGS and Medications

Alex Huang, MD

Controlling Wound Healing Following PRK

Farhad Hafezi, MD, PhD, FARVO

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS

PANORAMA Study Data

Rishi P. Singh, MD

Gene Therapy for Wet AMD

Szilárd Kiss, MD, explains the structure and 6-month results of the OPTIC trial, a phase 1 study that evaluated ADVM-022 (Adverum Biotechnologies), a novel intravitreal gene therapy for the treatment of wet age-related macular degeneration.

Posted: 10/21/2019


Please log in to leave a comment.

More From AAO: 2019 Coverage

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS